Seladelpar - CymaBay Therapeutics

Drug Profile

Seladelpar - CymaBay Therapeutics

Alternative Names: MBX 8025; RWJ 800025

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ortho-McNeil
  • Developer CymaBay Therapeutics
  • Class Acetates; Hepatoprotectants; Triazoles
  • Mechanism of Action C-reactive protein inhibitors; Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type V; Hyperlipoproteinaemia type I; Hyperlipoproteinaemia type IIa; Primary biliary cirrhosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperlipidaemia; Hyperlipoproteinaemia type IIa; Primary biliary cirrhosis
  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 08 Nov 2017 CymaBay Therapeutics plans a phase III trial for Primary biliary cirrhosis in 2018
  • 09 Oct 2017 CymaBay Therapeutics plans a phase II trial for Non-alcoholic steatohepatitis
  • 09 Oct 2017 CymaBay Therapeutics plans a phase II/III trial for Primary biliary cirrhosis (NCT03301506)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top